Patents Represented by Attorney, Agent or Law Firm David S. Resnick
-
Patent number: 5382519Abstract: Novel substantially pure periplasmic 3':5'-cyclic nucleotide phosphodiesterases are provided which are obtainable from gram negative bacterium capable of growing on restricted media containing cAMP or cGMP as a sole carbon source. Also provided is the isolated DNA coding for such enzymes and related methods of producing the same.Type: GrantFiled: January 13, 1993Date of Patent: January 17, 1995Assignee: Woods Hole Oceanographic InstitutionInventors: Paul V. Dunlap, Sean M. Callahan
-
Patent number: 5371745Abstract: An error correction apparatus for reproducing data that have been multi-encoded with error correcting codes and recorded on a recording medium, and for correcting errors contained in the reproduced data through decoding the same. The apparatus includes: a reproducing circuit for reproducing the data encoded and recorded on the recording medium; a memory for storing the reproduced data; an error correction circuit adapted to correct errors of the data with the error correcting codes from the lowest to the highest levels in due order, for detecting that correction is impossible at the highest level and at an intermediate level between the lowest and the highest levels and for outputting a first and a second correction incapability detecting signals, respectively; and a controller responsive to the first and second correction incapability detecting signals for controlling the reproduction circuit, the memory and the error correction circuit.Type: GrantFiled: May 17, 1990Date of Patent: December 6, 1994Assignee: Sharp Kabushiki KaishaInventors: Chitoku Kiyonaga, Kengo Sudoh
-
Patent number: 5366882Abstract: In accordance with the present invention there is provided an isolated DNA coding for the Bg/I restriction endonuclease and modification methylase derived from Bacillus globigii RUB561 stain, as well as related methods for cloning said recombinant DNA. The present invention also relates to clones which express recombinant Bg/I restriction endonuclease and recombinant modification methylase produced from Bg/I recombinant DNA and to methods for producing said enzymes.Type: GrantFiled: December 17, 1993Date of Patent: November 22, 1994Assignee: New England BiolabsInventors: Keith D. Lunnen, Geoffrey G. Wilson
-
Patent number: 5356311Abstract: A network wall plate includes a wall plate shell, a plurality of transmission-line adapting sockets removably installed on the wall plate shell, a plurality of transmission-line connectors which can be respectively plugged into the transmission-line adapting sockets, and two screw bases capable of passing therethrough screws to fix the wall plate onto a wall surface, wherein at least one of the transmission-line connectors can be removably plugged into one of the transmission-line adapting sockets. The present wall plate is designed to be diversified, to have an increased socket density and/or to provide an improved appearance.Type: GrantFiled: March 25, 1993Date of Patent: October 18, 1994Inventor: Danny Liu
-
Patent number: 5352778Abstract: Recombinant DNA polymeraset from archaebacteria as well as isolated DNA coding for such polymeraset are provided. The isolated DNA is obtained by use of DNA or antibody probet prepared from the DNA encoding T. litoralis DNA polymerate and the T. litoralis DNA polymerate respectively. Also provided are meshocs for producing recombinant archaebacteria thermostable DNA polymerase and methods for enhancing the expression of such polymeraset by identifying, locating and removing introns from within the DNA coding for such DNA polymerases.Type: GrantFiled: December 15, 1993Date of Patent: October 4, 1994Assignee: New England Biolabs, Inc.Inventors: Donald G. Comb, Francine Perler, Rebecca Kucera, William E. Jack
-
Patent number: 5348866Abstract: This invention relates to a DNA sequence comprising at least part of a porcine zona pellucida PZP-4.alpha. or -4.beta. gene coding for an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2, respectively, in SEQUENCE LISTING.This invention also relates to an expression system and to expression of said DNA.In addition, this invention relates to an immunogenic recombinant polypeptide or peptide which comprises at least part of said amino acid sequence and which is obtained by expressing said DNA, and to a contraceptive vaccine for use in human or other animals which comprises said polypeptide or peptide as an active ingredient.Type: GrantFiled: March 20, 1992Date of Patent: September 20, 1994Assignees: Shinzo Isojima, Tonen CorporationInventors: Shinzo Isojima, Akiko Akatani, Yuichi Okazaki, Masanobu Sugimoto
-
Patent number: 5328986Abstract: A novel growth factor (BTC-GF) was purified from the conditioned medium of pancreatic beta tumor cells initially derived from transgenic mice (RIPI-Tag2). The purification scheme included BioRex 70 chromatography, phenyl-Sepharose chromatography, TSL-GEL heparin FPLC and C4 reverse phase HPLC. The peptide also stimulated proliferation of bovine smooth muscle cells. It was not inactivated by boiling, by 10 mM dithiothreitol or by exposure to 1M acetic acid. Biological activity of BTC-GF was recovered from a single band of protein which had a molecular weight of 32,000 on SDS-PAGE.Type: GrantFiled: February 10, 1992Date of Patent: July 12, 1994Assignee: Children's Medical Center CorporationInventors: Moses J. Folkman, Yuen Shing
-
Patent number: 5324651Abstract: Human protein kinase C and rat protein kinase C, recombinant DNA containing DNA sequence coding for kinase C, a transformant transformed with a vector containing the above recombinant DNA, and the production method of human or rat kinase C by cultivating the transformant are disclosed.Kinase C is useful as reagent for studying cellular signal transduction mechanism, as diagnostic and inspection agent for disease, for example tumor, resulting from the trouble of cellular signal transduction mechanism, and as screening agent for a preventive agent or medicine to the disease.Type: GrantFiled: September 16, 1992Date of Patent: June 28, 1994Assignee: Takeda Chemical Industries, Ltd.Inventors: Ono Yoshitaka, Kurokawa Tsutomu, Igarashi Koichi, Nishizuka Yasutomi
-
Patent number: 5322785Abstract: There is provided an extremely thermostable enzyme obtainable from Thermococcus litoralis. The thermostable enzyme has a molecular weight of about 90,000-95,000 daltons, a half-life of about 60 minutes at 100.degree. C. in the absence of stabilizer, and a half-life of about 95 minutes at 100.degree. C. in the presence of stabilizer, such as octoxynol (TRITON X-100) or bovine serum albumin. The thermostable enzyme possesses a 3'-5' proofreading exonuclease activity. The thermostable enzyme may be native or recombinant and may be used for second-strand cDNA synthesis in cDNA cloning, DNA sequencing, and DNA amplification.Type: GrantFiled: April 17, 1991Date of Patent: June 21, 1994Assignee: New England Biolabs, Inc.Inventors: Donald G. Comb, Francine Perler, Rebecca Kucera, William E. Jack
-
Patent number: 5306808Abstract: Disclosed are a peptide derivative represented by the formula [I] or a pharmaceutically acceptable salt thereof: ##STR1## wherein A, B, C, D, E and F each represent amino acid residues, and satisfy any one condition of (i) A=Ser, B=Ser, C=Ser, D=Leu, E=Met and F=Phe, (ii) A=Ser, B=Ser, C=Ser, D=Trp, E=Leu and F=Phe, and (iii) A=Thr, B=Phe, C=Thr, D=Tyr, E=Lys and F=Tyr; and W, X, Y and Z each represent amino acid residues, and satisfy any one condition of (i) at least one of W and Y is an amino acid residue other than an L-alanine residue or other than an L-cysteine residue, (ii) X is an amino acid residue other than an L-Lysine residue, and (iii) Z is an amino acid residue other than an L-aspartic acid residue; (2) a method for producing the peptide derivative or the salt thereof; and (3) an agent for improving a circulatory function mainly comprising the peptide derivative or the salt thereof, such as a vasodilator or a vasoconstrictor.Type: GrantFiled: October 17, 1991Date of Patent: April 26, 1994Assignee: Takeda Chemical Industries, Ltd.Inventors: Mitsuhiro Wakimasu, Takashi Kikuchi, Kazuki Kubo
-
Patent number: 5298404Abstract: The present invention is directed to a method for cloning and producing the Hpa I restriction endonuclease by 1) introducing the restriction endonuclease gene from Haemophilus parainfluenzae into a host whereby the restriction gene is expressed; 2) fermenting the host which contains the vector encoding and expressing the Hpa I restriction endonuclease, and 3) purifying the Hpa I restriction endonuclease from the fermented host which contains the vector encoding and expressing the Hpa I restriction endonuclease activity.Type: GrantFiled: October 13, 1989Date of Patent: March 29, 1994Assignee: New England Biolabs, Inc.Inventors: Jack S. Benner, Phyllis Rees
-
Patent number: 5296371Abstract: The present invention is directed to a method for cloning and producing the Spiroplasma sp. strain MQ1 DNA methylase by (1) introducing the Spiroplasma methylase gene into a host whereby the methylase gene is expressed; (2) fermenting the host which contains the vector encoding and expressing the Spiroplasma methylase and (3) purifying the Spiroplasma methylase from the fermented host which contains the vector encoding and expressing the Spiroplasma DNA methylase activity.Type: GrantFiled: October 4, 1991Date of Patent: March 22, 1994Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem, an Israeli Corp.Inventors: Aharon Razin, Shlomo Rottem, Pinhas F. Renbaum
-
Patent number: 5290807Abstract: O-substituted fumagillol derivatives and its salts have an angiogenesis regressing activity are useful for treatment of diseases induced by abnormally stimulated neovascularization.Type: GrantFiled: July 21, 1992Date of Patent: March 1, 1994Assignee: Children's Medical Center CorporationInventors: Moses J. Folkman, Donald Ingber
-
Patent number: 5288696Abstract: The present invention is directed to a method for cloning and producing the SacII restriction endonuclease by 1) introducing the restriction endonuclease gene from Streptomyces achromogenes into a host whereby the restriction gene is expressed; 2) fermenting the host which contains the plasmid encoding and expressing the SacII restriction endonuclease activity, and 3) purifying the SacII restriction endonuclease from the fermented host which contains the plasmid encoding and expressing the SacII restriction endonuclease activity.Type: GrantFiled: September 7, 1990Date of Patent: February 22, 1994Assignee: New England Biolabs, Inc.Inventors: Ellen P. Guthrie, Marta M. Meda
-
Patent number: 5288722Abstract: The present invention relates to a compound of the formula: ##STR1## wherein R.sup.1 is 2-methyl-1-propenyl group or isobutyl group; R.sup.2 and R.sup.3 are each hydrogen atom, an optionally substituted hydrocarbon residue or an optionally substituted acyl group or R.sup.2 and R.sup.3 may form a ring together with the adjacent nitrogen atom; and the bonding mark .about. represents an .alpha.-linkage or .beta.-linkage, or a salt thereof. The compound (I) of the present invention has, among others, angiogenesis inhibiting activity, cell-growth inhibiting activity and immune reaction inhibiting activity, thus being useful as medicines, etc.Type: GrantFiled: September 19, 1991Date of Patent: February 22, 1994Assignee: Takeda Chemical Industries, Ltd.Inventors: Shoji Kishimoto, Shogo Marui, Takeshi Fujita
-
Patent number: 5248599Abstract: Disclosed is a DNA sequence containing a DNA segment coding for Achromobacter protease I (API) or variants thereof (referred to as T-API); a recombinant DNA constructed by introducing the DNA sequence in an expression vector so as to express the T-API; a transformant bearing the recombinant DNA; a process for producing the API which comprises cultivating the transformant, accumulating the T-API in a culture product, and recovering the same: and a protein of T-API. The cells transfected or transformed with the DNA sequence of the present invention allow for the production of a large amount of precursor protein of the T-API or the mature peptide.Type: GrantFiled: February 20, 1990Date of Patent: September 28, 1993Assignee: Waco Pure Chemical Industries, Ltd.Inventors: Fumio Sakiyama, Atsuo Nakata
-
Patent number: 5246845Abstract: The present invention provides a novel approach to the production of restriction enzymes. More specifically, there is provided a novel method for cloning these enzymes, which comprises preparing DNA libraries from the DNA of an organism that synthesizes the restriction enzyme of interest, creating a suitable host containing a heterospecific methyltransferase gene able to protectively modify DNA from digestion by the restriction enzyme of interest, introducing the DNA libraries into the protectively modified host, and screening recombinant organisms to identify those carrying the desired restriction enzyme gene.The application of this method to the FspI and HaeIII restriction genes of Fischerella species and Haemophilus aegyptius, respectively, is described in detail, together with the resulting clones that form the basis of a new and useful process for purifying the FspI and HaeIII restriction enzymes.Type: GrantFiled: October 27, 1992Date of Patent: September 21, 1993Assignee: New England Biolabs, Inc.Inventors: Geoffrey G. Wilson, Marta M. Meda
-
Patent number: 5242829Abstract: Monovalent and multivalent recombinant pox viruses which express immunogenic proteins of pseudorabies viruses are provided for use as live vaccines against pseudorabies virus. DNA vectors for recombination with pox virus to introduce one or more genes into a pox viral genome are also provided.Type: GrantFiled: March 6, 1990Date of Patent: September 7, 1993Assignee: Therion Biologics CorporationInventors: Dennis L. Panicali, Gail P. Mazzara, Linda R. Gritz
-
Patent number: 5233015Abstract: High-molecular weight synthetic resins of polyhexamethylene adipates are disclosed with molecular weights greater than about 10,000, preferably greater than about 30,000, and a viscosity at 100.degree. C. of at least about 300 poise, preferably exceeding 6000.The polymerization is carried out with a ratio of diol/acid in the range 0.990 to about 1.03, preferably in the range of about 1.001 to about 1.01.Type: GrantFiled: March 21, 1991Date of Patent: August 3, 1993Assignee: Bostik, Inc.Inventors: Reginald T. Agger, Joginder S. Johl
-
Patent number: 5229493Abstract: A novel growth factor (BTC-CG) was purified from the conditioned medium of pancreatic beta tumor cells initially derived from transgenic mice (RIPl-Tag2). The purification scheme included BioRex 70 chromatography, phenyl-Sepharose chromatography, TSL-GEL heparin FPLC and C4 reverse phase HPLC. The peptide also stimulated proliferation of bovine smooth muscle cells. It was not inactivated by boiling, by 10 mM dithiothreitol or by exposure to IM acetic acid. Biological activity of BTC-GF was recovered from a single band of protein which had a molecular weight of 2,000 on SDS-PAGE. The Partial N-terminal amino acid sequence of this protein was determined with an ABI 470A protein sequencer as: Asp-Gly-[X]-Thr-[X]-Arg-Thr-Pro-Glu-[X]-Asn-Gly.Type: GrantFiled: October 26, 1990Date of Patent: July 20, 1993Assignee: Children's Medical Center CorporationInventors: Moses J. Folkman, Yuen Shing